MeiraGTx Holdings plc (MGTX)
| Market Cap | 921.46M +147.4% |
| Revenue (ttm) | 79.76M +131.1% |
| Net Income | -120.53M |
| EPS | -1.49 |
| Shares Out | 92.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 520,692 |
| Open | 10.53 |
| Previous Close | 10.65 |
| Day's Range | 9.87 - 10.63 |
| 52-Week Range | 5.11 - 11.85 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 28.25 (+183.92%) |
| Earnings Date | May 14, 2026 |
About MGTX
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal ... [Read more]
Financial Performance
In 2025, MeiraGTx Holdings's revenue was $81.39 million, an increase of 144.57% compared to the previous year's $33.28 million. Losses were -$114.20 million, -22.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MGTX stock is "Strong Buy." The 12-month stock price target is $28.25, which is an increase of 183.92% from the latest price.
News
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Com...
MeiraGTx reports Q1 EPS (57c), consensus (45c)
Reports Q1 revenue $293,000 vs. $1.93M last year. “Our achievements in the first few months of 2026 have materially strengthened MeiraGTx (MGTX) – we are now in a position to…
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostom...
MeiraGTx Holdings Earnings release: Q1 2026
MeiraGTx Holdings released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
MeiraGTx Holdings Quarterly report: Q1 2026
MeiraGTx Holdings has published its Q1 2026 quarterly earnings report on May 14, 2026.
MeiraGTx Holdings Transcript: Bank of America Global Healthcare Conference 2026
Major progress includes regaining RPGR rights, advancing pivotal xerostomia and Parkinson's programs, and leveraging in-house manufacturing to accelerate regulatory filings. Durable clinical data and strong physician networks support targeted commercialization and premium pricing.
MeiraGTx Holdings Proxy statement: Proxy filing
MeiraGTx Holdings filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
MeiraGTx Holdings Proxy statement: Proxy filing
MeiraGTx Holdings filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
MeiraGTx price target raised to $30 from $26 at Piper Sandler
Piper Sandler raised the firm’s price target on MeiraGTx (MGTX) to $30 from $26 and keeps an Overweight rating on the shares following the company’s long-term data update in xerostomia…
MeiraGTx price target raised to $24 from $16 at RBC Capital
RBC Capital raised the firm’s price target on MeiraGTx (MGTX) to $24 from $16 and keeps an Outperform rating on the shares. The company’s 3-year follow-up data from the Phase…
MeiraGTx announces three-year data from Phase 1 AQUAx study
MeiraGTx (MGTX) announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia. “Today we are very pleased to…
MeiraGTx Holdings Transcript: KOL event
Three-year phase I data for AAV-AQP1 in persistent RIX show robust, durable efficacy and safety, with transformative, disease-modifying effects and high physician and payer support. The therapy targets a large, concentrated market, with pivotal data and BLA filing expected in 2027 and a U.S. launch in 2028.
MeiraGTx Holdings Press release: KOL event
MeiraGTx Holdings issued a press release on April 16, 2026, disclosing material business information to investors.
MeiraGTx Holdings Slides: KOL event
MeiraGTx Holdings has posted slides in relation to its latest quarterly earnings report, which was published on April 16, 2026.
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an under...
MeiraGTx announces acquisition of bota-vec for treatment of XLRP
MeiraGTx (MGTX) announced that it has entered into an asset purchase agreement with Johnson & Johnson (JNJ) to acquire all interests in bota-vec for the treatment of X-linked Retinitis Pigmentosa,…
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered int...
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced positive three-year dat...
MeiraGTx Holdings Slides: Corporate presentation
MeiraGTx Holdings has posted slides in relation to its latest quarterly earnings report, which was published on April 16, 2026.
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for b...
MeiraGTx price target lowered to $18 from $20 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on MeiraGTx (MGTX) to $18 from $20 and keeps an Outperform rating on the shares. The firm adjusted targets for…
MeiraGTx price target lowered to $26 from $30 at Piper Sandler
Piper Sandler lowered the firm’s price target on MeiraGTx (MGTX) to $26 from $30 and keeps an Overweight rating on the shares following a FY25 update. The firm continues to…
MeiraGTx price target raised to $16 from $14 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $16 from $14 and keeps a Buy rating on the shares. The FDA’s Breakthrough Therapy Designation for…
MeiraGTx Holdings Annual report: Q4 2025
MeiraGTx Holdings has published its Q4 2025 annual report on March 26, 2026.
MeiraGTx Holdings Earnings release: Q4 2025
MeiraGTx Holdings released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.